US2016296644A1PendingUtilityA1

Anticancer drug, comprising a copper radioisotope

28
Assignee: VALENTINI GIANLUCAPriority: Nov 21, 2013Filed: Oct 24, 2014Published: Oct 13, 2016
Est. expiryNov 21, 2033(~7.3 yrs left)· nominal 20-yr term from priority
Inventors:Gianluca Valentini
A61P 35/00A61P 25/28A61K 51/02
28
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The object of the present invention is a drug for the therapeutic treatment of tumours, also usable as diagnostic agent and therapeutic agent for the Alzheimer's disease. Such drug comprises a copper-64 radioisotope in its salt form, said drug consisting of copper-64 chloride (64CuCl2).

Claims

exact text as granted — not AI-modified
1 . Drug containing the salt form Cl 2  of copper-64 radioisotope  64 Cu, characterised in that
 said drug copper-64 chloride  64 CuCl 2  is aimed to a direct use in patients, as a substance employable per se and without bond with other complex molecules,   and in that   each mL of solution of said drug  64 CuCl 2  contains 925 MBq of  64 Cu at the calibration time of 01h00 a.m. CET, corresponding to at least 0.25 micrograms of said  64 Cu.   
     
     
         2 . Drug according to  claim 1 ,
 characterised in that   every vial of said drug  64 CuCl 2  has a volume between 1 and 3 mL and activity range between 925 and 2,775 MBq, corresponding to an accumulation of  64 Cu between at least 0.25 and 0.75 micrograms.   
     
     
         3 . Drug according to  claim 1 ,
 characterised in that   its unit dose for effectiveness is equal to 1.5 Bq for every cell towards which said drug  64 CuCl 2  is targeted.   
     
     
         4 - 27 . (canceled) 
     
     
         28 . Drug according to  claim 1 ,
 characterised in that   it can be employed for the therapeutic treatment of a solid tumour, such as pancreatic, prostate, brain, breast, ovary, head-neck, oesophagus, stomach, intestines, colon, lung cancer.   
     
     
         29 . Drug according to  claim 28 ,
 characterised in that it is administered intravenously or arteriously loco-regionally.   
     
     
         30 . Drug according to  claim 29 ,
 characterised in that it is administered in a dosage customised for the specific patient wherein the dosage is on the average equal to 3,700 MBq.   
     
     
         31 . Drug according to  claim 28 ,
 characterised in that it is administered a first time on a first day and a second time on the next day.   
     
     
         32 . Drug according to  claim 28 ,
 characterised in that the administration is repeated every three months.   
     
     
         33 . Drug according to  claim 1 ,
 characterised in that it can be employed for the treatment of a neuroendocrine tumour.   
     
     
         33 . Drug according to  claim 33 ,
 characterised in that it is administered intravenously or arteriously loco-regionally.   
     
     
         35 . Drug according to claim  34 ,
 characterised in that it is administered in a dosage customised for the specific patient wherein the dosage is on the average equal to 3,700 MBq.   
     
     
         36 . Drug according to  claim 33 ,
 characterised in that it is administered a first time on a first day and a second time on the next day.   
     
     
         37 . Drug according to  claim 33 ,
 characterised in that the administration is repeated every three months.   
     
     
         38 . Drug according to  claim 1 ,
 characterised in that it can be employed for the treatment of a melanoma.   
     
     
         39 . Drug according to  claim 38 ,
 characterised in that it is administered intravenously or arteriously loco-regionally.   
     
     
         40 . Drug according to  claim 39 ,
 characterised in that it is administered in a dosage customised for the specific patient wherein the dosage is on the average equal to 3,700 MBq.   
     
     
         41 . Drug according to  claim 38 ,
 characterised in that it is administered a first time on a first day and a second time on the next day.   
     
     
         42 . Drug according to  claim 38 ,
 characterised in that the administration is repeated every three months.   
     
     
         43 . Drug according to  claim 1 ,
 characterised in that   it can be employed for the treatment of leukaemia or a lymphoma.   
     
     
         44 . Drug according to  claim 43 ,
 characterised in that   it is administered intravenously or arteriously loco-regionally.   
     
     
         45 . Drug according to  claim 44 ,
 characterised in that it is administered in a dosage customised for the specific patient wherein the dosage is on the average equal to 3,700 MBq.   
     
     
         46 . Drug according to  claim 43 ,
 characterised in that it is administered a first time on a first day and a second time on the next day.   
     
     
         47 . Drug according to  claim 43 , characterised in that the administration is repeated every three months. 
     
     
         48 . Drug according to  claim 1 ,
 characterised in that   it can be employed for the diagnosis of the Alzheimer's disease.   
     
     
         49 . Drug according to  claim 48 ,
 characterised in that   it is administered intravenously or arteriously loco-regionally.   
     
     
         50 . Drug according to  claim 49 ,
 characterised in that it is administered in a dosage customised for the specific patient wherein the dosage is on the average equal to 370 MBq.   
     
     
         51 . Drug according to  claim 48 ,
 characterised in that it is administered a first time on a first day and a second time on the next day.   
     
     
         52 . Drug according to  claim 48 ,
 characterised in that the administration is repeated every three months.   
     
     
         53 . Drug according to  claim 1 ,
 characterised in that   it can be employed for the therapeutic treatment of the Alzheimer's disease.   
     
     
         54 . Drug according to  claim 53 ,
 characterised in that   it is administered intravenously or arteriously loco-regionally.   
     
     
         55 . Drug according to  claim 54 ,
 characterised in that it is administered in a dosage customised for the specific patient wherein the dosage is on the average equal to 3,700 MBq.   
     
     
         56 . Drug according to  claim 53 ,
 characterised in that it is administered a first time on a first day and a second time on the next day.   
     
     
         57 . Drug according to  claim 53 ,
 characterised in that the administration is repeated every three months.

Join the waitlist — get patent alerts

Track US2016296644A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.